Pain Management Drugs Market 2028 By Therapeutics, Indication and Geography | The Insight Partners

Pain Management Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Therapeutics (Anticonvulsants, Antidepressants, Anesthetics, Non-steroidal Anti-inflammatory Drugs (NSAIDS), Opioids, Antimigraine Agents, Other Non-narcotic Analgesic); Indication (Neuropathic Pain, Fibromyalgia, Arthritic Pain, Chronic Back Pain, Migraine, Post-Operative Pain, Cancer Pain) and Geography

Report Code: TIPRE00004067 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming

MARKET OVERVIEW



Pain is a disturbing sensory and emotional sensation that occurs as a result of tissue injury or disease. Various conditions such as, osteoarthritis, multiple sclerosis,chronic arthritis, stomach ulcers, fibromyalgia, diabetic neuropathy, and cancer, can also cause discomfort. The length of pain varies from short-term acute pain to long-term chronic pain. Acute pain can be mild and last a few moment or weeks or months. Chronic pain is brought on by ageing bones and joints, nerve loss, or injury. A variety of agents are utilized to manage pain resulting from inflammation in response to tissue damage, chemical agents/pathogens (nociceptive pain) or nerve damage (neuropathic pain). Most drugs act by binding to protein targets of cell membranes and affecting biochemical processes of the body.

MARKET SCOPE



The "Global Pain Management Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the pain management drugs market with detailed market segmentation by therapeutics and indication. The report provides key statistics on the market status of the leading pain management drugs market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION



  •   Based on therapeutics the market is segmented as, Anticonvulsants, Antidepressants, Anesthetics, Non-steroidal Anti-inflammatory Drugs (NSAIDS), Opioids, Antimigraine Agents and Other Non-narcotic Analgesic.
  •   Based on indication the market is segmented as, Neuropathic Pain, Fibromyalgia, Arthritic Pain, Chronic Back Pain, Migraine, Post-Operative Pain and Cancer Pain.

MARKET DYNAMICS


Drivers:



  •   Growing geriatric population across the globe.
  •   Rising prevalence of chronic diseases and chronic pain arising from condtions like cancer, diabetic neuropathy, osteoporesis etc.
  •   Growing number of surgical procedures and rising healthcare expenditures.
  •   Increasing sport related injuries are also expected to spur the market growth.

Restraints:



  •   However, issues such as, patent expiration, drug abuse and exploitation are expected to restrain market growth during the forecast period.

REGIONAL FRAMEWORK



The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The pain management drugs market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the pain management drugs market in these regions.

IMPACT OF COVID-19 ON PAIN MANAGEMENT DRUGS MARKET



COVID-19 first began in Wuhan (China) during December 2019 and since then it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, the UK, Turkey, Italy, and Spain are some of the worst affected countries in terms confirmed cases and reported deaths. The COVID-19 has been affecting economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. Shutdown of various plants and factories has affected the global supply chains and negatively impacted the manufacturing, delivery schedules, and sales of products in global market. Few companies have already announced possible delays in product deliveries and slump in future sales of their products. According to the current market situation, the report further assesses the present and future effects of the COVID-19 pandemic on the overall market, giving more reliable and authentic projections In addition to this, the global travel bans imposed by countries in Europe, Asia-Pacific, and North America are affecting the business collaborations and partnerships opportunities.

MARKET PLAYERS



The report covers key developments in the pain management drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the marketwere acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market payers from pain management drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for pain management drugs in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the pain management drugs market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
  •   Abbott
  •   Endo International plc
  •   AstraZeneca
  •   Lilly
  •   GlaxoSmithKline Plc.
  •   Johnson and Johnson
  •   Teva Pharmaceutical Industries Ltd.
  •   Mallinckrodt
  •   Novartis AG
  •   Merck Sharp and Dohme Corp
    The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
  • The List of Companies

    - Abbott
    - Endo International plc
    - AstraZeneca
    - Lilly
    - GlaxoSmithKline Plc.
    - Johnson and Johnson
    - Teva Pharmaceutical Industries Ltd.
    - Mallinckrodt
    - Novartis AG
    - Cipla Inc
    - Dr. Reddy's Laboratories
    - Alkem Labs
    - Intas Pharmaceuticals, Ltd
    - Torrent Pharmaceuticals Ltd
    TIPRE00004067
    Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

    Get the Latest COVID-19 Analysis on this market




    Have a question?

    Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

    Speak To Analyst
    Pricing
    • $3000
    • $4550
    • $6550
    • $8550

    Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

        Inquire for Discount